By Sriparna Roy March 16 (Reuters) - Cannabis-based medicines have shown little evidence of effectiveness for treating most ...

A new analysis represents the largest effort yet to systematically parse all the data from high-quality clinical trials on ...

There’s ‘no evidence’ marijuana works to treat most mental health disorders, largest review of its kind finds - More than 52 ...

Leading Australian psychiatrists say the findings should serve as a wake-up call for the government to better regulate the $1 ...

A new study out of Australia says there's no evidence that marijuana relieves anxiety, depression or PTSD. The paper was ...

EDMONTON, AB, June 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has expanded their popular IndiMed brand with the ...

Increasing numbers of Australians are using medicinal cannabis for anxiety, depression, insomnia, substance disorders and ...

A landmark Lancet Psychiatry paper published today – the largest-ever review of the safety and efficacy of cannabinoids ...

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray Brands") (NASDAQ: TLRY and TSX: TLRY) and a global leader in medical cannabis, empowering the ...

Researchers examined 54 clinical trials to see if cannabis helps treat mental health or addiction issues. They found minimal proof of benefit, alongside a higher risk of mild side effects like ...

Years in the making, the Canadian LP is finding markets closer to the pharmaceutical industry in highly regulated medical cannabis markets.

Chief Financial Officer Simona King outlined the company’s recent strategic pivot toward medical cannabis and international ...